Prices Climb at Home, Fall Everywhere Else

May 18, 2026

Verdant Research collaborated with the AARP Policy Institute to put hard numbers on something patients have felt for years: brand name drugs keep getting more expensive in the US long after they hit the market, while the same drugs get cheaper almost everywhere else.

The numbers
We looked at the 25 brand name drugs with no generic or biosimilar competition that drove the most Medicare Part D spending in 2024. Together these are responsible for more than $100 billion in spending and used by nearly 15 million beneficiaries. The list price was tracked from launch through April 2026 and showed:

  • US list prices rose an average of 81% over each drug's lifetime on the market.
  • Prices for the same drugs fell an average of 13% across 19 other high-income countries in our companion analysis.
  • 24 of the 25 drugs got more expensive in the US, with increases ranging from 14% to a staggering 873% (Enbrel). Only one drug, Repatha, saw a net US price decline. That was the result of a one-time 60% cut back in 2018 due to competitive pressure.
  • Meanwhile, 24 of the 25 drugs got cheaper abroad, with declines from 1% to 42%. Only one ticked up slightly (1%).

Policy can lower drug prices
Other high-income countries have regulatory mechanisms that pull prices down after launch. The US largely doesn't and manufacturers are free to set higher launch prices than in peer countries and then raise those prices repeatedly.

Still, US policy changes are starting to have tangible impacts. Six of the 25 drugs (Linzess, Jardiance, Eliquis, Januvia, Imbruvica, and Ibrance) saw a one-time US list price cut between 2024 and 2026, averaging a sizable 40% drop, since they were negotiated by Medicare. Other drugs have also cut list prices to avoid paying more in inflation rebates to Medicare and Medicaid. 

But: Six other drugs in the study have also been negotiated by Medicare and have not dropped list prices. For these drugs, list prices will remain above what Medicare pays, so that commercial insurers and cash-paying patients will continue to pay more.

Why it matters
These findings land at a moment when the Trump Administration is actively pursuing most-favored-nation pricing, aiming to give Americans access to lower prices of drugs in other countries. MFN points to several other ways that the US can address high drug pricing through existing policy mechanisms:

  1. Integrating international price comparisons directly into Medicare's negotiation process,
  2. Negotiating prices earlier (closer to launch, as other countries do), or
  3. Expanding which drugs are eligible for negotiation in the first place.

Read the full report here.